Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
González-Billalabeitia E, Seitzer N, Song SJ, Song MS, Patnaik A, Liu XS, Epping MT, Papa A, Hobbs RM, Chen M, Lunardi A, Ng C, Webster KA, Signoretti S, Loda M, Asara JM, Nardella C, Clohessy JG, Cantley LC, Pandolfi PP.
González-Billalabeitia E, et al. Among authors: hobbs rm.
Cancer Discov. 2014 Aug;4(8):896-904. doi: 10.1158/2159-8290.CD-13-0230. Epub 2014 May 27.
Cancer Discov. 2014.
PMID: 24866151
Free PMC article.